Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 01)
Leflunomide Tablet, Film Coated
Product Images NDC 50090-7537
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 50090-7537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 02)
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 03)
This text discusses the percentage of ACR 20 responders at endpoint in different trials involving medications such as Leflunomide, Methotrexate, Placebo, and Sulfasalazine. The data includes results from Tral 1 and Tral 2 trials over 2 months.*
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 04)
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 05)
Change in Sharp Score. The document provides numerical data related to changes in Sharp scores over time for different treatments, including leflunomide, methotrexate, sulfasalazine, and placebo. The information includes values at 12, 24, and 36 months. This data seems to be related to a study or analysis of the efficacy of these treatments for a certain condition.*
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 06)
Label Image (Lbl500907537)
This product is identified as No. 2143-0 and contains 20 MG of an unnamed substance. It comes with 30 tablets and is likely used for medicinal purposes. The specific use of the product is not clearly mentioned in the provided text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
